Sienna Biopharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$30.91
-0.0
-0.26
13
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of aesthetics and medical dermatology. The company is headquartered in Westlake Village, California and currently employs 13 full-time employees. The company went IPO on 2017-07-27. The firm is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The firm's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of aesthetics and medical dermatology. The company is headquartered in Westlake Village, California and currently employs 13 full-time employees. The company went IPO on 2017-07-27. The firm is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The firm's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.